Next Article in Journal
Differences in Insomnia Symptoms between Immigrants and Non-Immigrants in Switzerland attributed to Emotional Distress: Analysis of the Swiss Health Survey
Previous Article in Journal
The Influencing Factors of Haze Tolerance in China
Previous Article in Special Issue
An Inventory Model for Deteriorating Drugs with Stochastic Lead Time
Article Menu
Issue 2 (January-2) cover image

Export Article

Open AccessArticle
Int. J. Environ. Res. Public Health 2019, 16(2), 288; https://doi.org/10.3390/ijerph16020288

Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System

1
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
2
Department of Pharmaceutical Engineering, Hoseo University, Asan 31499, Korea
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 19 November 2018 / Revised: 8 January 2019 / Accepted: 12 January 2019 / Published: 21 January 2019
(This article belongs to the Special Issue Societal Side Effects: The Wider Impact of Pharmaceuticals on Society)
Full-Text   |   PDF [2041 KB, uploaded 21 January 2019]   |  

Abstract

This study reviews and evaluates the national drug formulary system used to improve patient access to new drugs by making reimbursement decisions for new drugs as part of the South Korean national health insurance system. The national health insurance utilizes three methods for improving patient access to costly drugs: risk-sharing agreements, designation of essential drugs, and a waiver of cost-effectiveness analysis. Patients want reimbursement for new drugs to be processed quickly to improve their access to these drugs, whereas payers are careful about listing them given the associated financial burden and the uncertainty in cost-effectiveness. However, pharmaceutical companies are advocating for drug prices above certain thresholds to maintain global pricing strategies, cover the costs of drug development, and fund future investments into research and development. The South Korean government is expected to develop policies that will improve patient access to drugs with unmet needs for broadening health insurance coverage. Simultaneously, the designing of post-listing management methods is warranted for effectively managing the financial resources of the national health insurance system. View Full-Text
Keywords: patient access; reimbursement; risk-sharing agreement; cost-effectiveness analysis; national health insurance patient access; reimbursement; risk-sharing agreement; cost-effectiveness analysis; national health insurance
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Yoo, S.-L.; Kim, D.-J.; Lee, S.-M.; Kang, W.-G.; Kim, S.-Y.; Lee, J.H.; Suh, D.-C. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System. Int. J. Environ. Res. Public Health 2019, 16, 288.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top